Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 21:00:00 31/05/2024 BST 		5-day change 1st Jan Change
3.65 CAD -4.20% Intraday chart for Eupraxia Pharmaceuticals Inc. -6.41% -32.03%
05-23 Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT
05-23 Eupraxia Pharmaceuticals Inc. Brief: Announcing Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 34.89 78.81 146.5 130 - -
Enterprise Value (EV) 1 34.89 64.62 146.5 130 130 130
P/E ratio -1.32 x - - - - -
Yield - - - - - -
Capitalization / Revenue - - - - - 2.88 x
EV / Revenue - - - - - 2.88 x
EV / EBITDA - -3.42 x -3.9 x -4.33 x -4.33 x -
EV / FCF - -4,129,724 x - - - -
FCF Yield - -0% - - - -
Price to Book - 5.48 x - 2.64 x 9.51 x 2.02 x
Nbr of stocks (in thousands) 14,243 21,593 27,282 35,623 - -
Reference price 2 2.450 3.650 5.370 3.650 3.650 3.650
Announcement Date 29/03/22 23/03/23 01/04/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - 45.22
EBITDA 1 - - - -23.06 -37.6 -30 -30 -
EBIT 1 - - - -23.2 - -50.77 -57.7 -19.62
Operating Margin - - - - - - - -43.39%
Earnings before Tax (EBT) - - - - - - - -
Net income -7.176 -3.997 - - - - - -
Net margin - - - - - - - -
EPS -0.2900 -0.6500 -1.850 - - - - -
Free Cash Flow - - - -19.08 - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 10/02/21 30/03/21 29/03/22 23/03/23 01/04/24 - - -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 - - - - -8.802 -4.787 -7.649 -8.884 - -6.693 -11.65 -11.65 -18.3 - -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - - -
Net income - -3.691 - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - - -
EPS -0.2200 -0.2600 - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 29/03/22 05/05/22 12/08/22 07/11/22 23/03/23 11/05/23 11/08/23 14/11/23 01/04/24 08/05/24 - - - - -
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - 14.2 - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - -19.1 - - - -
ROE (net income / shareholders' equity) - - - -186% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets - - - - - - - -
Book Value Per Share 1 - - - 0.6700 - 1.380 0.3800 1.810
Cash Flow per Share 1 - - - -0.9700 -1.160 1.040 -1.000 1.440
Capex 2 - - - 0.31 0.1 - - -
Capex / Sales - - - - - - - -
Announcement Date 10/02/21 30/03/21 29/03/22 23/03/23 01/04/24 - - -
1CAD2CAD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.65 CAD
Average target price
14.45 CAD
Spread / Average Target
+295.89%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EUPRAXIA PHARMACEUTICALS INC. Stock Eupraxia Pharmaceuticals Inc.
-32.03% 95.3M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. Financials Eupraxia Pharmaceuticals Inc.